127 related articles for article (PubMed ID: 19631839)
1. [Pharmacoeconomic analysis: results of the REACH registry].
Suárez C; Abadía C; Echevarria A
Med Clin (Barc); 2009 Sep; 132 Suppl 2():41-3. PubMed ID: 19631839
[TBL] [Abstract][Full Text] [Related]
2. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
[TBL] [Abstract][Full Text] [Related]
3. One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
Mahoney EM; Wang K; Cohen DJ; Hirsch AT; Alberts MJ; Eagle K; Mosse F; Jackson JD; Steg PG; Bhatt DL;
Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):38-45. PubMed ID: 20031786
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
Uchiyama S; Goto S; Matsumoto M; Nagai R; Origasa H; Yamazaki T; Shigematsu H; Shimada K; Yamada N; Bhatt DL; Steg PG; Ikeda Y;
J Neurol Sci; 2009 Dec; 287(1-2):45-51. PubMed ID: 19815240
[TBL] [Abstract][Full Text] [Related]
5. [Implications of the REACH registry for neurologists].
Roquer J
Med Clin (Barc); 2009 Sep; 132 Suppl 2():30-3. PubMed ID: 19631836
[TBL] [Abstract][Full Text] [Related]
6. In Germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis--results from the REACH registry.
Parhofer KG; Zeymer U; Stark RG; Binz C; Schwertfeger M; Bhatt DL; Steg PG; Röther J;
Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):51-6. PubMed ID: 19834877
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA).
Monreal M; Alvarez L; Vilaseca B; Coll R; Suárez C; Toril J; Sanclemente C;
Eur J Intern Med; 2008 May; 19(3):192-7. PubMed ID: 18395163
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics of patients with cerebrovascular disease in the REACH registry: the Spanish contribution.
Suárez C;
Cerebrovasc Dis; 2007; 24 Suppl 1():89-95. PubMed ID: 17971643
[TBL] [Abstract][Full Text] [Related]
9. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease.
Smolderen KG; Wang K; de Pouvourville G; Brüggenjürgen B; Röther J; Zeymer U; Parhofer KG; Steg PG; Bhatt DL; Magnuson EA;
Eur J Vasc Endovasc Surg; 2012 Feb; 43(2):198-207. PubMed ID: 22001145
[TBL] [Abstract][Full Text] [Related]
10. [One-year data from the REACH registry in Spain].
Suárez C; Polo IG; Ibáñez P
Med Clin (Barc); 2009 Sep; 132 Suppl 2():10-4. PubMed ID: 19631832
[TBL] [Abstract][Full Text] [Related]
11. The burden of peripheral artery disease and the role of antiplatelet therapy.
Aronow H; Hiatt WR
Postgrad Med; 2009 Jul; 121(4):123-35. PubMed ID: 19641278
[TBL] [Abstract][Full Text] [Related]
12. National health care costs of peripheral arterial disease in the Medicare population.
Hirsch AT; Hartman L; Town RJ; Virnig BA
Vasc Med; 2008 Aug; 13(3):209-15. PubMed ID: 18687757
[TBL] [Abstract][Full Text] [Related]
13. [Implications of the REACH registry for vascular surgery].
Alvarez-Fernández LJ; Vallina-Victorero Vázquez MJ; Ramos Gallo MJ; Santiago MV
Med Clin (Barc); 2009 Sep; 132 Suppl 2():25-9. PubMed ID: 19631835
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment and cost of cardiovascular disease in Australia.
Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
[TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular complications at 1-year of follow-up in patients with atherothrombosis. On behalf of Spain's REACH Registry].
Suárez C; Castillo J; Esmatjes E; Sala J; Cairols M; Montoto C; Barberá G;
Med Clin (Barc); 2009 Apr; 132(14):537-44. PubMed ID: 19393390
[TBL] [Abstract][Full Text] [Related]
16. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.
Kauf TL; Velazquez EJ; Crosslin DR; Weaver WD; Diaz R; Granger CB; McMurray JJ; Rouleau JL; Aylward PE; White HD; Califf RM; Schulman KA
Am Heart J; 2006 Jan; 151(1):206-12. PubMed ID: 16368320
[TBL] [Abstract][Full Text] [Related]
17. [Implications of the REACH registry for cardiologists].
de la Villa Redondo BG
Med Clin (Barc); 2009 Sep; 132 Suppl 2():15-20. PubMed ID: 19631833
[TBL] [Abstract][Full Text] [Related]
18. [Use of drugs in the REACH registry: from guidelines to clinical practice].
Gómez Cerezo JF
Med Clin (Barc); 2009 Sep; 132 Suppl 2():44-6. PubMed ID: 19631840
[TBL] [Abstract][Full Text] [Related]
19. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
Smolderen KG; Bell A; Lei Y; Cohen EA; Steg PG; Bhatt DL; Mahoney EM;
Can J Cardiol; 2010 Oct; 26(8):297-305. PubMed ID: 20931098
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and excess costs among patients with cardiovascular disease.
Ademi Z; Liew D; Zomer E; Gorelik A; Hollingsworth B; Steg PG; Bhatt DL; Reid CM
Heart Lung Circ; 2013 Sep; 22(9):724-30. PubMed ID: 23510668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
